Clinical trials: Polymorphous Light Eruption
Polymorphic Light Eruption (PLE)
Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
The purpose of this study is to determine whether the afamelanotide (CUV1647) formulation is effective in preventing PLE episodes or reducing the severity of PLE symptoms in patients with a well documented history of the disease.
- Trial name
- NCT00472901
- Testing
- Afamelanotide (CUV1647)
- Where
- 3 sites in Australia, Austria and 1 more
- Volunteers
- 18 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Polymorphic Light Eruption
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).
- Trial name
- NCT04704713
- Testing
- Afamelanotide
- Volunteers
- 31 people
- Sponsor
- Clinuvel Pharmaceuticals Limited